In "Beyond Diagnosis: CLL," Cleveland Clinic hematologist/oncologist Allison Winter, MD, and host John Mangels continue their conversation on communicating ...

Most patients initiated full-dose ibrutinib, while reduced starting doses clustered in older, more comorbid, poorer ECOG cohorts, indicating clinician-driven personalization rather than cardiovascular ...

Four zanubrutinib trials in R/R CLL/SLL were pooled using random-effects modeling, with heterogeneous designs (including open-label and single-arm cohorts) and variable AE reporting. Overall ...

SIERRA VISTA — After a futile federal probe of the childhood leukemia cluster in Sierra Vista, fear of the disease is growing, not waning, prompting a new state study to find out if adults here are ...

SPIRIT-HF, another spironolactone trial in HFpEF; the ESSENCE imaging study of the drug olezarsen; the SirPAD trial in peripheral artery disease; and ultrasound-guided femoral venous access are the ...